RVMD Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of -12425.36%. Revolution Medicines, Inc.'s return on equity of -51.27% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Revolution Medicines, Inc. has a consensus price target of $84.11, signalling downside risk potential of -18.11%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 338%. Given that Perspective Therapeutics, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Revolution Medicines, Inc..

Revolution Medicines, Inc. has a beta of 0.990, which suggesting that the stock is 1.046% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.

Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Revolution Medicines, Inc.'s net income of -$305.2M is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 190.53x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Disc Medicine, Inc. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of --. Revolution Medicines, Inc.'s return on equity of -51.27% beat Disc Medicine, Inc.'s return on equity of -32.82%.

Revolution Medicines, Inc. has a consensus price target of $84.11, signalling downside risk potential of -18.11%. On the other hand Disc Medicine, Inc. has an analysts' consensus of $121.67 which suggests that it could grow by 50.32%. Given that Disc Medicine, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Disc Medicine, Inc. is more attractive than Revolution Medicines, Inc..

Revolution Medicines, Inc. has a beta of 0.990, which suggesting that the stock is 1.046% less volatile than S&P 500. In comparison Disc Medicine, Inc. has a beta of 0.870, suggesting its less volatile than the S&P 500 by 13.012%.

Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Disc Medicine, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Disc Medicine, Inc. pays out -- of its earnings as a dividend.

Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Disc Medicine, Inc. quarterly revenues of --. Revolution Medicines, Inc.'s net income of -$305.2M is lower than Disc Medicine, Inc.'s net income of -$62.3M. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Disc Medicine, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus -- for Disc Medicine, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of 31.72%. Revolution Medicines, Inc.'s return on equity of -51.27% beat Eli Lilly & Co.'s return on equity of 106.26%.

Revolution Medicines, Inc. has a consensus price target of $84.11, signalling downside risk potential of -18.11%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,098.04 which suggests that it could fall by -0.91%. Given that Revolution Medicines, Inc. has more downside risk than Eli Lilly & Co., analysts believe Eli Lilly & Co. is more attractive than Revolution Medicines, Inc..

Revolution Medicines, Inc. has a beta of 0.990, which suggesting that the stock is 1.046% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.54% to investors and pays a quarterly dividend of $1.50 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Revolution Medicines, Inc.'s net income of -$305.2M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 54.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 17.00x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Solid Biosciences, Inc. has a net margin of -- compared to Revolution Medicines, Inc.'s net margin of --. Revolution Medicines, Inc.'s return on equity of -51.27% beat Solid Biosciences, Inc.'s return on equity of -77.74%.

Revolution Medicines, Inc. has a consensus price target of $84.11, signalling downside risk potential of -18.11%. On the other hand Solid Biosciences, Inc. has an analysts' consensus of $15.23 which suggests that it could grow by 171.49%. Given that Solid Biosciences, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Solid Biosciences, Inc. is more attractive than Revolution Medicines, Inc..

Revolution Medicines, Inc. has a beta of 0.990, which suggesting that the stock is 1.046% less volatile than S&P 500. In comparison Solid Biosciences, Inc. has a beta of 2.688, suggesting its more volatile than the S&P 500 by 168.768%.

Revolution Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solid Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revolution Medicines, Inc. pays -- of its earnings as a dividend. Solid Biosciences, Inc. pays out -- of its earnings as a dividend.

Revolution Medicines, Inc. quarterly revenues are --, which are smaller than Solid Biosciences, Inc. quarterly revenues of --. Revolution Medicines, Inc.'s net income of -$305.2M is lower than Solid Biosciences, Inc.'s net income of -$45.8M. Notably, Revolution Medicines, Inc.'s price-to-earnings ratio is -- while Solid Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revolution Medicines, Inc. is -- versus 20.36x for Solid Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.